Cargando…
Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors
We investigated the distribution of antibodies neutralizing SARS-CoV-2 according to age, sex or blood group in French blood donors. In 464 samples collected before the emergence of SARS-CoV-2 (2017 and 2018), our virus neutralization assay had a 100% specificity. It was used to test 998 samples coll...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362788/ https://www.ncbi.nlm.nih.gov/pubmed/32679056 http://dx.doi.org/10.1016/j.antiviral.2020.104880 |
_version_ | 1783559557505613824 |
---|---|
author | Gallian, Pierre Pastorino, Boris Morel, Pascal Chiaroni, Jacques Ninove, Laetitia de Lamballerie, Xavier |
author_facet | Gallian, Pierre Pastorino, Boris Morel, Pascal Chiaroni, Jacques Ninove, Laetitia de Lamballerie, Xavier |
author_sort | Gallian, Pierre |
collection | PubMed |
description | We investigated the distribution of antibodies neutralizing SARS-CoV-2 according to age, sex or blood group in French blood donors. In 464 samples collected before the emergence of SARS-CoV-2 (2017 and 2018), our virus neutralization assay had a 100% specificity. It was used to test 998 samples collected from blood donors during the last week of March or the first week of April 2020. As expected at this stage of the outbreak, the prevalence was low (2.7%) and, importantly, criteria for blood donation imply that the vast majority of seropositives had asymptomatic or pauci-symptomatic SARS-CoV-2 infections. Seroprevalence values did not differ significantly among age groups (but were slightly higher in donors <30yo and ≥60yo), and between males and females (2.82% vs 2.69%), unlike what has been observed regarding hospitalizations admission to ICU and death rates in France. By contrast, we observed that the proportion of seropositives was significantly lower in group O donors (1.32% vs 3.86% in other donors, p = 0.014). We conclude that virus infection seems to occur with a similar incidence in men and women among French blood donors, but that blood group O persons are less at risk of being infected and not only of suffering from severe clinical presentations, as previously suggested. |
format | Online Article Text |
id | pubmed-7362788 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73627882020-07-16 Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors Gallian, Pierre Pastorino, Boris Morel, Pascal Chiaroni, Jacques Ninove, Laetitia de Lamballerie, Xavier Antiviral Res Short Communication We investigated the distribution of antibodies neutralizing SARS-CoV-2 according to age, sex or blood group in French blood donors. In 464 samples collected before the emergence of SARS-CoV-2 (2017 and 2018), our virus neutralization assay had a 100% specificity. It was used to test 998 samples collected from blood donors during the last week of March or the first week of April 2020. As expected at this stage of the outbreak, the prevalence was low (2.7%) and, importantly, criteria for blood donation imply that the vast majority of seropositives had asymptomatic or pauci-symptomatic SARS-CoV-2 infections. Seroprevalence values did not differ significantly among age groups (but were slightly higher in donors <30yo and ≥60yo), and between males and females (2.82% vs 2.69%), unlike what has been observed regarding hospitalizations admission to ICU and death rates in France. By contrast, we observed that the proportion of seropositives was significantly lower in group O donors (1.32% vs 3.86% in other donors, p = 0.014). We conclude that virus infection seems to occur with a similar incidence in men and women among French blood donors, but that blood group O persons are less at risk of being infected and not only of suffering from severe clinical presentations, as previously suggested. Published by Elsevier B.V. 2020-09 2020-07-15 /pmc/articles/PMC7362788/ /pubmed/32679056 http://dx.doi.org/10.1016/j.antiviral.2020.104880 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Gallian, Pierre Pastorino, Boris Morel, Pascal Chiaroni, Jacques Ninove, Laetitia de Lamballerie, Xavier Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors |
title | Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors |
title_full | Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors |
title_fullStr | Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors |
title_full_unstemmed | Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors |
title_short | Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors |
title_sort | lower prevalence of antibodies neutralizing sars-cov-2 in group o french blood donors |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362788/ https://www.ncbi.nlm.nih.gov/pubmed/32679056 http://dx.doi.org/10.1016/j.antiviral.2020.104880 |
work_keys_str_mv | AT gallianpierre lowerprevalenceofantibodiesneutralizingsarscov2ingroupofrenchblooddonors AT pastorinoboris lowerprevalenceofantibodiesneutralizingsarscov2ingroupofrenchblooddonors AT morelpascal lowerprevalenceofantibodiesneutralizingsarscov2ingroupofrenchblooddonors AT chiaronijacques lowerprevalenceofantibodiesneutralizingsarscov2ingroupofrenchblooddonors AT ninovelaetitia lowerprevalenceofantibodiesneutralizingsarscov2ingroupofrenchblooddonors AT delamballeriexavier lowerprevalenceofantibodiesneutralizingsarscov2ingroupofrenchblooddonors |